Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients with Advanced Lung Adenocarcinoma

This study is testing a personalized immune cell therapy called GTE-001 — made from the patient's own tumor-infiltrating lymphocytes (immune cells extracted from their tumor) — in people with advanced lung adenocarcinoma (a type of non-small cell lung cancer) that has progressed despite prior treatment. **You may be eligible if...** - You are 18 or older with confirmed advanced lung adenocarcinoma - Your cancer has progressed after first-line chemotherapy or after recurrence - Your general health is good enough to tolerate the treatment (ECOG 0–1) - You have at least one measurable tumor and expected survival of at least 3 months **You may NOT be eligible if...** - You have previously received engineered cell therapy (like CAR-T cells) or an organ transplant - You have active autoimmune disease - You have brain metastases that are untreated or symptomatic - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.